Banque Pictet & Cie SA trimmed its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 59.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,233 shares of the medical instruments supplier’s stock after selling 23,967 shares during the period. Banque Pictet & Cie SA’s holdings in DENTSPLY SIRONA were worth $971,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Commonwealth Bank of Australia boosted its position in DENTSPLY SIRONA by 19.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares during the period. Acrospire Investment Management LLC purchased a new stake in DENTSPLY SIRONA during the 2nd quarter worth $113,000. Dupont Capital Management Corp purchased a new stake in DENTSPLY SIRONA during the 2nd quarter worth $116,000. Massey Quick Simon & CO. LLC purchased a new stake in DENTSPLY SIRONA during the 3rd quarter worth $124,000. Finally, Korea Investment CORP boosted its position in DENTSPLY SIRONA by 139.9% during the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after purchasing an additional 1,251 shares during the period. 94.65% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/19/dentsply-sirona-inc-xray-shares-sold-by-banque-pictet-cie-sa.html.
DENTSPLY SIRONA Inc. (NASDAQ XRAY) traded up $0.37 during trading hours on Friday, reaching $67.55. 1,390,000 shares of the company’s stock were exchanged, compared to its average volume of 2,142,495. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. The stock has a market cap of $15,515.09, a PE ratio of 26.91, a P/E/G ratio of 2.67 and a beta of 1.27. DENTSPLY SIRONA Inc. has a one year low of $52.53 and a one year high of $67.95.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.66 EPS. analysts predict that DENTSPLY SIRONA Inc. will post 2.66 earnings per share for the current year.
In related news, insider Mark Thierer bought 77,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were acquired at an average price of $66.04 per share, for a total transaction of $5,085,080.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Francis J. Lunger sold 8,900 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Corporate insiders own 1.99% of the company’s stock.
XRAY has been the subject of a number of research reports. BidaskClub cut shares of DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Cleveland Research cut shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research report on Thursday, October 5th. Barrington Research raised shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 price target for the company in a research report on Monday, November 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $69.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $67.00.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.